Argos Therapeutics Inc (ARGS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Argos Therapeutics Inc (ARGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7955
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Argos Therapeutics Inc (Argos) is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platform. Its Arcelis-based immunotherapies use the patient’s dendritic cells to activate an immune response specific to the patient’s disease. Argos also offers AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. The company use biology of dendritic cells to activate the immune response. Argos is headquartered in Durham, North Carolina, the US.

Argos Therapeutics Inc (ARGS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Argos Therapeutics Raises US$60 Million In Series E Financing 13
Argos Therapeutics Raises US$16 Million In Venture Financing 16
Argos Therapeutics Raises US$25 Million In Series D Financing 17
Partnerships 19
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Licensing Agreements 21
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters Into Licensing Agreement With Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Equity Offering 27
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37
Argos Therapeutics Completes IPO For USD49.8 Million 39
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41
Debt Offering 42
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42
Argos Therapeutics Inc – Key Competitors 43
Argos Therapeutics Inc – Key Employees 44
Argos Therapeutics Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Financial Announcements 46
Apr 02, 2018: Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 46
Nov 09, 2017: Argos Reports Third Quarter 2017 Financial Results and Operational Highlights 49
Aug 09, 2017: Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 51
Corporate Communications 53
Jul 18, 2018: Delisting of Securities of Rosetta Genomics, ConvergeOne Holdings, (Warrant Only), FC Global Realty, Concordia International, and Argos Therapeutics from The Nasdaq Stock Market 53
Sep 26, 2017: Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors 54
Other Significant Developments 55
Nov 28, 2017: Argos Provides Financial Update 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Argos Therapeutics Raises US$60 Million In Series E Financing 13
Argos Therapeutics Raises US$16 Million In Venture Financing 16
Argos Therapeutics Raises US$25 Million In Series D Financing 17
Argos Therapeutics Enters into Research Agreement with Personalis 19
Invetech Enters into Agreement with Argos Therapeutics 20
Argos Therapeutics to Enter into Option Agreement with Pharmstandard and Actigen 21
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 22
Argos Enters Into Licensing Agreement With Medinet 23
Pharmstandard Enters into Licensing Agreement with Argos Therapeutics 24
Green Cross Enters into Licensing Agreement with Argos Therapeutics 25
Argos Therapeutics to Raise USD6.3 Million in Public Offering of Shares 27
Argos Therapeutics to Raise USD1.5 Million in Private Placement of Shares 28
Argos Therapeutics Plans to Raise Funds through Private Placement of Shares 29
Argos Therapeutics to Raise Funds through Private Placement of Shares 30
Argos Therapeutics Raises USD5.5 Million in Public Offering of Shares 31
Argos Therapeutics Raises USD50 Million in Public Offering of Shares and Warrants 32
Argos Therapeutics Plans to Raise up to USD124 Million in Public Offering of Shares 34
Argos Therapeutics Raises USD29.8 Million in Second Tranche of Private Placement of Shares and Warrants 35
Argos Therapeutics Plans to Raise up to USD36 Million in Public Offering of Shares 36
Argos Therapeutics Raises USD20 Million in First Tranche Private Placement of Shares and Warrants 37
Argos Therapeutics Completes IPO For USD49.8 Million 39
Argos Therapeutics Raises USD12 Million in Private Placement of Shares and Warrants 41
Argos Therapeutics Raises USD6 Million in Private Placement of 9.5% Convertible Promissory Notes Due 2022 42
Argos Therapeutics Inc, Key Competitors 43
Argos Therapeutics Inc, Key Employees 44
Argos Therapeutics Inc, Subsidiaries 45

List of Figures
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Argos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Argos Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Argos Therapeutics Inc (ARGS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HDI-Global SE:企業の戦略・SWOT・財務情報
    HDI-Global SE - Strategy, SWOT and Corporate Finance Report Summary HDI-Global SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Altona Energy Plc:企業の戦略・SWOT・財務分析
    Altona Energy Plc - Strategy, SWOT and Corporate Finance Report Summary Altona Energy Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Aradigm Corp (ARDM):企業の財務・戦略的SWOT分析
    Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Country Road Group Pty Ltd:企業の戦略的SWOT分析
    Country Road Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Toyota Industries Corporation:企業の戦略・SWOT・財務情報
    Toyota Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • IndigoVision Group plc (IND):企業の財務・戦略的SWOT分析
    Summary IndigoVision Group plc (IndigoVision) is a developer, manufacturer and distributor of end-to-end IP security management systems. The company’s products include management software, cameras and encoders, specialized cameras, body worn video, integration and recorders. Its camera and encoder’s …
  • Realtek Semiconductor Corp. (2379):企業の財務・戦略的SWOT分析
    Realtek Semiconductor Corp. (2379) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Alltech Inc:企業の戦略的SWOT分析
    Alltech Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GP Batteries International Ltd:企業の戦略的SWOT分析
    GP Batteries International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Nuance Communications Inc (NUAN):企業の財務・戦略的SWOT分析
    Nuance Communications Inc (NUAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Bukwang Pharm Co Ltd (003000):製薬・医療:M&Aディール及び事業提携情報
    Summary Bukwang Pharm Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexid, thioctacid, levovir, legalon, Orfil, azeptin, lonasen, ixel, and asima, among others. Its pipeline products comprise …
  • Swissquote Group Holding Ltd (SQN):企業の財務・戦略的SWOT分析
    Swissquote Group Holding Ltd (SQN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • SThree Plc (STHR):企業の財務・戦略的SWOT分析
    Summary SThree Plc (Sthree) is a staffing company that offers permanent and contract staffing business. The company operates through its sectors such as information and communications technology (ICT), energy, engineering, life sciences, banking and finance. Its business brands such as Computer Futu …
  • Mediware Information Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mediware Information Systems Inc (Mediware) is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solutions are equipped in blood banks …
  • Link Health Group:製薬・医療:M&Aディール及び事業提携情報
    Summary Link Health Group (Link Health) is a pharmaceutical company focused on the discovery and development of novel drug candidates for the treatment of cancer and other diseases. Its pipeline product portfolio includes LH011, an oral small molecule serine protease inhibitor for treating pancreati …
  • Qualicaps Inc:企業の戦略的SWOT分析
    Qualicaps Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Volvo Car Corporation:企業の戦略・SWOT・財務分析
    Volvo Car Corporation - Strategy, SWOT and Corporate Finance Report Summary Volvo Car Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Repsol Sinopec Resources UK Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Repsol Sinopec Resources UK Ltd (Repsol Sinopec), formerly Talisman Sinopec Energy UK Ltd is an oil and gas company that offers exploration services. The company explores, discovers, and produces oil and gas across the North Sea. It provides operation in floating facilities, offshore platfor …
  • Bayerische Patentallianz GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Bayerische Patentallianz GmbH (Bayerische Patentallianz) is a central patent and marketing agency that evaluates and markets the inventions, protecting, marketing and achieving financial benefits. The agency provides support and consulting services to small and medium businesses and free inv …
  • DP World Ltd:企業の戦略的SWOT分析
    DP World Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆